Michael Celano - 17 Jan 2024 Form 4 Insider Report for Larimar Therapeutics, Inc. (LRMR)

Role: Chief Financial Officer
Signature: /s/ Jennifer Johansson, Attorney-in-fact
Issuer symbol: LRMR
Transactions as of: 17 Jan 2024
Net transactions value: $0
Form type: 4
Filing time: 19 Jan 2024, 16:32:58 UTC
Previous filing: 18 May 2023
Next filing: 24 Jan 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LRMR	Common Stock	Award	$0	+31,250	+28%	$0.000000	143,996	17 Jan 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LRMR	Stock Option (Right to Buy)	Award	$0	+187,500		$0.000000	187,500	17 Jan 2024	Common Stock	187,500	$4.21	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F2	The option vests 25% on January 17, 2025, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.